Trading sessions saw BSX stock price steady at $73.50, supported by a positive revision in industry-wide medtech forecasts. Investors continue to monitor innovation cycles for sustainable returns. Moreover, BSX currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> . Boston Scientific (NYSE:BSX) has seen its stock price surge over 30% in the past twelve months, significantly outpacing the S&P 500’s 9% gain. This impressive performance is attributed to new product launches, which have bolstered sales growth and expanded profit margins. However, the crucial question for investors is whether BSX stock, currently trading around $100, presents a compelling buying opportunity. We think that at its present valuation, Boston Scientific appears relatively expensive, particularly when compared to the broader market and its own historical metrics. That said, if you seek upside with lower volatility than individual stocks, the Trefis High-Quality portfolio presents an alternative – having outperformed the S&P 500 and generated returns exceeding 91% since its inception. Separately, see – Will Adobe Stock See Higher Levels? The BSX stock price recently tested a high of $74.20, driven by optimism over new product approvals in Europe. Analysts believe the firm’s R&D investments could enhance gross margins by 100 basis points over the next quarters.